Verra M. Ngwa

Verra M. Ngwa

Auto-generated profile, based on publicly available information

Verra M. Ngwa

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
DEDeanna N. Edwards
Deanna N. Edwards
VNVerra M. Ngwa
Verra M. Ngwa
ARAriel L. Raybuck
Ariel L. Raybuck
SWShan Wang
Shan Wang
YHYoonha Hwang
Yoonha Hwang
JCJin Chen
Jin Chen
Rapidly proliferating tumor and immune cells need metabolic programs that support energy and biomass production. The amino acid glutamine is consumed by effector T cells and glutamine-addicted triple-negative breast cancer (TNBC) cells, suggesting that a metabolic competition for glutamine may exist within the tumor microenvironment, potentially serving as a therapeutic intervention strategy. Here, we report that there is an inverse correlation between glutamine metabolic genes and markers of T cell–mediated cytotoxicity in human basal-like breast cancer (BLBC) patient data sets, with increased glutamine metabolism and decreased T cell cytotoxicity associated with poor survival. We found that tumor cell–specific loss of glutaminase (GLS), a key enzyme for glutamine metabolism, improved antitumor T cell activation in both a spontaneous mouse TNBC model and orthotopic grafts. The glutamine transporter inhibitor V-9302 selectively blocked glutamine uptake by TNBC cells but not CD8+ T cells, driving synthesis of glutathione, a major cellular antioxidant, to improve CD8+ T cell effector function. We propose a “glutamine steal” scenario, in which cancer cells deprive tumor-infiltrating lymphocytes of needed glutamine, thus impairing antitumor immune responses. Therefore, tumor-selective targeting of glutamine metabolism may be a promising therapeutic strategy in TNBC.

26 May 2023 in Science Immunology
Verified
Journal Article
Closed access
LWLihong Wang-Bishop
Lihong Wang-Bishop
BKBlaise Russel Kimmel
Blaise Russel Kimmel
VNVerra M. Ngwa
Verra M. Ngwa
MMMatthew Z. Madden
Matthew Z. Madden
JBJessalyn J. Baljon
Jessalyn J. Baljon
JWJohn T. Wilson
John T. Wilson
The tumor-associated vasculature imposes major structural and biochemical barriers to the infiltration of effector T cells and effective tumor control. Correlations between stimulator of interferon genes (STING) pathway activation and spontaneous T cell infiltration in human cancers led us to evaluate the effect of STING-activating nanoparticles (STANs), which are a polymersome-based platform for the delivery of a cyclic dinucleotide STING agonist, on the tumor vasculature and attendant effects on T cell infiltration and antitumor function. In multiple mouse tumor models, intravenous administration of STANs promoted vascular normalization, evidenced by improved vascular integrity, reduced tumor hypoxia, and increased endothelial cell expression of T cell adhesion molecules. STAN-mediated vascular reprogramming enhanced the infiltration, proliferation, and function of antitumor T cells and potentiated the response to immune checkpoint inhibitors and adoptive T cell therapy. We present STANs as a multimodal platform that activates and normalizes the tumor microenvironment to enhance T cell infiltration and function and augments responses to immunotherapy.

5 December 2017 in Science Signaling
Verified
Journal Article
Closed access
DEDeanna N. Edwards
Deanna N. Edwards
VNVerra M. Ngwa
Verra M. Ngwa
SWShan Wang
Shan Wang
ESEileen Shiuan
Eileen Shiuan
DBDana M. Brantley-Sieders
Dana M. Brantley-Sieders
JCJin Chen
Jin Chen
By activating the transcription cofactors YAP and TAZ, the receptor EphA2 mediates a metabolic switch to glutamine dependency in HER2 + breast cancers.

21 July 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
VNVerra M. Ngwa
Verra M. Ngwa
DEDeanna N. Edwards
Deanna N. Edwards
YHYoonha Hwang
Yoonha Hwang
BKBreelyn Karno
Breelyn Karno
XWXiaoyong Wang
Xiaoyong Wang
JCJin Chen
Jin Chen
Glutamine is the most abundant nonessential amino acid in blood stream; yet its concentration in tumor interstitium is markedly lower than that in the serum, reflecting the huge demand of various cell types in tumor microenvironment for glutamine. While many studies have investigated glutamine metabolism in tumor epithelium and infiltrating immune cells, the role of glutamine metabolism in tumor blood vessels remains unknown. Here, we report that inducible genetic deletion of glutaminase (GLS) specifically in host endothelium, GLSECKO, impairs tumor growth and metastatic dissemination in vivo. Loss of GLS decreased tumor microvascular density, increased perivascular support cell coverage, improved perfusion, and reduced hypoxia in mammary tumors. Importantly, chemotherapeutic drug delivery and therapeutic efficacy were improved in tumor-bearing GLSECKO hosts or in combination with GLS inhibitor, CB-839. Mechanistically, loss of GLS in tumor endothelium resulted in decreased leptin levels, and exogenous recombinant leptin rescued tumor growth defects in GLSECKO mice. Together, these data demonstrate that inhibition of endothelial glutamine metabolism normalizes tumor vessels, reducing tumor growth and metastatic spread, improving perfusion, reducing hypoxia, and enhancing chemotherapeutic delivery. Thus, targeting glutamine metabolism in host vasculature may improve clinical outcome in patients with solid tumors.Significance: This study demonstrates a crucial role for glutamine metabolism in tumor endothelium, which may be exploited therapeutically to induce vascular normalization and improve drug delivery in solid tumors.

4 April 2023
Verified
Other
Open access
VNVerra M. Ngwa
Verra M. Ngwa
DEDeanna N. Edwards
Deanna N. Edwards
YHYoonha Hwang
Yoonha Hwang
BKBreelyn Karno
Breelyn Karno
XWXiaoyong Wang
Xiaoyong Wang
JCJin Chen
Jin Chen
Glutamine is the most abundant nonessential amino acid in blood stream; yet its concentration in tumor interstitium is markedly lower than that in the serum, reflecting the huge demand of various cell types in tumor microenvironment for glutamine. While many studies have investigated glutamine metabolism in tumor epithelium and infiltrating immune cells, the role of glutamine metabolism in tumor blood vessels remains unknown. Here, we report that inducible genetic deletion of glutaminase (GLS) specifically in host endothelium, GLSECKO, impairs tumor growth and metastatic dissemination in vivo. Loss of GLS decreased tumor microvascular density, increased perivascular support cell coverage, improved perfusion, and reduced hypoxia in mammary tumors. Importantly, chemotherapeutic drug delivery and therapeutic efficacy were improved in tumor-bearing GLSECKO hosts or in combination with GLS inhibitor, CB-839. Mechanistically, loss of GLS in tumor endothelium resulted in decreased leptin levels, and exogenous recombinant leptin rescued tumor growth defects in GLSECKO mice. Together, these data demonstrate that inhibition of endothelial glutamine metabolism normalizes tumor vessels, reducing tumor growth and metastatic spread, improving perfusion, reducing hypoxia, and enhancing chemotherapeutic delivery. Thus, targeting glutamine metabolism in host vasculature may improve clinical outcome in patients with solid tumors.Significance:This study demonstrates a crucial role for glutamine metabolism in tumor endothelium, which may be exploited therapeutically to induce vascular normalization and improve drug delivery in solid tumors.

4 April 2023
Verified
Other
Open access
VNVerra M. Ngwa
Verra M. Ngwa
DEDeanna N. Edwards
Deanna N. Edwards
YHYoonha Hwang
Yoonha Hwang
BKBreelyn Karno
Breelyn Karno
XWXiaoyong Wang
Xiaoyong Wang
JCJin Chen
Jin Chen
This figure shows immunofluorescence images of increased apoptosis (Cleaved- Caspase 3) in GLSECKO tumors compared to WT while there was no significant change in proliferation (Ki-67). Quantification of these data were shown in Figure 1G and 1H.